# Ipamorelin Safe — A safety ledger of what the literature actually says

> An authored reading of the ipamorelin safety record: one short Phase 2 trial, FDA aggregation and immunogenicity concerns, no chronic human data, and a gray-market supply that flunks the basics. For research purposes only.

The molecule is one of the cleanest-looking growth-hormone secretagogues ever characterized in a rat. The human record is shorter than most readers assume, and the supply chain is the part nobody talks about.

## What this site is — and is not

Ipamorelin Safe is an independent editorial project that reads the ipamorelin literature the way a careful quarterly would read it: page by page, distinction by distinction, with the gaps drawn in as clearly as the findings. The publication is not a clinic. It is not a pharmacy. It does not employ clinicians, it does not write prescriptions, and it does not sell anything.

The domain carries the word 'safe' because safety is the editorial subject — not because the editors are claiming the molecule is safe in any human use. Ipamorelin is not approved by the FDA, the EMA, or any other major regulator for any indication [5]. The largest human safety dataset in the published literature is one short Phase 2 trial in 114 postoperative bowel-resection patients [3]. Most of what is said online about ipamorelin's safety rests on that single seven-day intravenous study, on the preclinical selectivity work from 1998 [1], and on the structural absence of obvious red flags in the rat record. The honest reading is that absence-of-finding is not the same as evidence-of-absence — particularly when no chronic human study exists [4].

## Why ipamorelin has the cleanest preclinical profile in its class

The molecule is a synthetic pentapeptide — five amino acids, three of them unnatural, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. It activates the growth hormone secretagogue receptor 1a (GHSR-1a) on pituitary somatotrophs, the same receptor endogenous ghrelin activates. In the foundational characterization, ipamorelin released growth hormone with potency comparable to GHRP-6 but did not raise adrenocorticotropic hormone or cortisol above the baseline produced by GHRH alone — even at exposures greater than two hundred times the GH ED50 [1].

That selectivity is the central safety claim made for ipamorelin against earlier growth-hormone-releasing peptides. It is real. It is also acute. The 1998 work was rat and swine pharmacology over short windows; the human PK/PD characterization that followed [2] was a single-dose study in eight male volunteers per dose level. Selectivity at the receptor is not a guarantee of safety in chronic exposure, and the downstream effects of repeatedly elevating growth hormone and insulin-like growth factor 1 — fluid retention, peripheral edema, arthralgia, carpal-tunnel-type symptoms, reduced peripheral insulin sensitivity — are class effects of any agent that meaningfully moves the GH axis [11]. They have not been quantified for ipamorelin in chronic human use because no chronic human ipamorelin study exists.

## The clinical record, in one paragraph

The deepest published human PK/PD work on ipamorelin used five escalating fifteen-minute IV infusions in eight healthy male volunteers per dose group, modeled terminal half-life at approximately two hours, and reported acute tolerability at every dose level [2]. The largest published clinical trial randomized 114 adults undergoing open or laparoscopic bowel resection to 0.03 mg/kg IV ipamorelin twice daily versus placebo for up to seven days [3]; the primary efficacy endpoint missed (median time to first tolerated solid meal 25.3 hours in the ipamorelin arm versus 32.6 hours in placebo, P=0.15), and treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo — a comparable rate against a high surgical background. A second Helsinn-sponsored Phase 2 study (NCT01280344) completed but did not lead to a regulatory submission; the postoperative-ileus development program was discontinued, and ipamorelin has never advanced to Phase 3 for any indication [4]. That is the entire registered human record.

## The FDA's 2024 reading, briefly

On October 29, 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed both ipamorelin acetate and ipamorelin free base for inclusion in the 503A Bulks Regulation. The agency recommended against inclusion of either form [5]. The briefing record cites specific concerns about peptide aggregation in injectable subcutaneous formulations, the immunogenicity implications of aggregation, and the difficulty of characterizing impurities in a peptide built from unnatural amino acids (Aib, D-2-Nal, D-Phe) [6]. The same regulatory record references a serious adverse event including death in a development-stage IV protocol — a route- and protocol-specific event, but on the record nonetheless [7].

The practical consequence is that there is no FDA-sanctioned compounding pathway for ipamorelin in the United States as of late 2024. Its removal from the interim 503B Category 2 list, effective September 27, 2024, was a procedural consequence of a withdrawn nomination — not an FDA endorsement of safety [5].

## How to read this site

Each content page below is a chapter in the same ledger. /research walks the literature in the order it was published. /dosage describes the doses that have actually appeared in published rodent and human protocols, in research context only. /faq answers the questions that recur in search behavior around 'ipamorelin safety.' /references is the full numbered citation list with DOIs and PubMed links. /about explains what this publication is and is not. /contact tells you how to write to the editors.

Nothing on this site is medical advice, a recommendation, or an endorsement. The editorial position is that the ipamorelin literature deserves a careful authored reading and that the most honest version of that reading is also the most useful one.

## References

[1] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
[2] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416.
[3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
[4] Helsinn Therapeutics (US), Inc. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov NCT01280344. 2014.
[5] U.S. FDA. FDA Briefing Document, PCAC Meeting (October 29, 2024) — Ipamorelin Acetate and Ipamorelin (free base) review for 503A Bulks Regulation. 2024.
[6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — aggregation, immunogenicity, and unnatural amino acid characterization concerns. 2024.
[7] U.S. FDA; Hone Health and ProPublica summaries. FDA Briefing Document on Ipamorelin (PCAC, October 2024) — serious adverse event reference. 2024.
[11] Buscail E, Deraison C. Postoperative ileus: A pharmacological perspective. British Journal of Pharmacology. 2022;179(13):3283-3305.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.